Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review

Background: On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this,...

Full description

Bibliographic Details
Main Authors: Kome Gbinigie, Kerstin Frie
Format: Article
Language:English
Published: Royal College of General Practitioners 2020-04-01
Series:BJGP Open
Subjects:
Online Access:https://bjgpopen.org/content/4/2/bjgpopen20X101069
_version_ 1818314456937005056
author Kome Gbinigie
Kerstin Frie
author_facet Kome Gbinigie
Kerstin Frie
author_sort Kome Gbinigie
collection DOAJ
description Background: On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease. Aim: To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19. Design & setting: A rapid review of the literature was conducted. Method: Electronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020. Results: There is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (n = 30 and n = 36) and suffer methodological limitations. No medium or long-term follow-up data is available. Conclusion: At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.
first_indexed 2024-12-13T08:49:56Z
format Article
id doaj.art-ffb760c5080d4a589535b5df4d13ecb8
institution Directory Open Access Journal
issn 2398-3795
language English
last_indexed 2024-12-13T08:49:56Z
publishDate 2020-04-01
publisher Royal College of General Practitioners
record_format Article
series BJGP Open
spelling doaj.art-ffb760c5080d4a589535b5df4d13ecb82022-12-21T23:53:24ZengRoyal College of General PractitionersBJGP Open2398-37952020-04-014210.3399/bjgpopen20X101069Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid reviewKome Gbinigie0Kerstin Frie1GP and Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKPost-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKBackground: On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease. Aim: To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19. Design & setting: A rapid review of the literature was conducted. Method: Electronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020. Results: There is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (n = 30 and n = 36) and suffer methodological limitations. No medium or long-term follow-up data is available. Conclusion: At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.https://bjgpopen.org/content/4/2/bjgpopen20X101069covid-19coronaviruschloroquinehydroxychloroquineprimary healthcaregeneral practice
spellingShingle Kome Gbinigie
Kerstin Frie
Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
BJGP Open
covid-19
coronavirus
chloroquine
hydroxychloroquine
primary healthcare
general practice
title Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
title_full Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
title_fullStr Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
title_full_unstemmed Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
title_short Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
title_sort should chloroquine and hydroxychloroquine be used to treat covid 19 a rapid review
topic covid-19
coronavirus
chloroquine
hydroxychloroquine
primary healthcare
general practice
url https://bjgpopen.org/content/4/2/bjgpopen20X101069
work_keys_str_mv AT komegbinigie shouldchloroquineandhydroxychloroquinebeusedtotreatcovid19arapidreview
AT kerstinfrie shouldchloroquineandhydroxychloroquinebeusedtotreatcovid19arapidreview